Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Dr. Lal PathLabs Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Dr. Lal PathLabs wird ein jährliches Gewinn- und Umsatzwachstum von 14.8% bzw. 10.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 22% betragen.

Wichtige Informationen

14.7%

Wachstumsrate der Gewinne

14.6%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	25.8%
Wachstumsrate der Einnahmen	10.4%
Zukünftige Eigenkapitalrendite	21.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	16 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BSE:539524 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	31,219	5,593	6,465	7,300	10
3/31/2026	27,938	4,884	5,800	6,406	21
3/31/2025	24,970	4,185	5,083	5,443	20
3/31/2024	22,266	3,577	4,779	5,354	N/A
12/31/2023	21,722	3,298	N/A	N/A	N/A
9/30/2023	21,227	3,013	4,767	5,198	N/A
6/30/2023	20,552	2,638	N/A	N/A	N/A
3/31/2023	20,169	2,388	4,115	4,560	N/A
12/31/2022	20,114	2,435	N/A	N/A	N/A
9/30/2022	20,189	2,480	-824	3,884	N/A
6/30/2022	19,835	2,713	N/A	N/A	N/A
3/31/2022	20,874	3,448	-294	4,467	N/A
12/31/2021	20,329	3,669	N/A	N/A	N/A
9/30/2021	19,884	4,041	4,609	5,327	N/A
6/30/2021	19,219	3,944	N/A	N/A	N/A
3/31/2021	15,813	2,916	3,386	3,982	N/A
12/31/2020	14,520	2,407	N/A	N/A	N/A
9/30/2020	13,275	2,003	2,259	2,821	N/A
6/30/2020	12,612	1,955	N/A	N/A	N/A
3/31/2020	13,304	2,259	2,043	2,839	N/A
12/31/2019	13,298	2,405	N/A	N/A	N/A
9/30/2019	12,944	2,322	2,199	2,619	N/A
6/30/2019	12,463	2,086	N/A	N/A	N/A
3/31/2019	12,034	1,992	1,765	2,185	N/A
12/31/2018	11,691	1,923	N/A	N/A	N/A
9/30/2018	11,393	1,825	N/A	N/A	N/A
6/30/2018	10,999	1,761	N/A	N/A	N/A
3/31/2018	10,569	1,707	1,246	1,971	N/A
12/31/2017	10,100	1,617	N/A	N/A	N/A
9/30/2017	9,548	1,565	N/A	N/A	N/A
6/30/2017	9,389	1,586	N/A	N/A	N/A
3/31/2017	9,124	1,546	N/A	1,713	N/A
12/31/2016	8,902	1,576	N/A	N/A	N/A
9/30/2016	8,713	1,876	N/A	N/A	N/A
6/30/2016	8,249	1,413	N/A	N/A	N/A
3/31/2016	7,913	1,322	N/A	1,585	N/A
12/31/2015	7,654	1,201	N/A	N/A	N/A
3/31/2015	6,596	908	N/A	1,218	N/A
3/31/2014	5,579	763	N/A	980	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 539524Das prognostizierte Gewinnwachstum (14.8% pro Jahr) liegt über der Sparquote (6.7%).

Ertrag vs. Markt: 539524Die Erträge des Unternehmens (14.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (16% pro Jahr).

Hohe Wachstumserträge: 539524Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 539524Die Einnahmen des Unternehmens (10.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (9.4% pro Jahr).

Hohe Wachstumseinnahmen: 539524Die Einnahmen des Unternehmens (10.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 539524Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (22%)

Dr. Lal PathLabs Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 8.0% to ₹2,353

Price target increased by 7.2% to ₹2,091

Price target decreased to ₹2,536

Consensus EPS estimates fall by 16%

Price target decreased to ₹2,829

Price target increased to ₹3,286

Recent updates

MD & Director recently sold ₹37m worth of stock

Upcoming dividend of ₹6.00 per share

MD & Director recently sold ₹29m worth of stock

MD & Director recently sold ₹36m worth of stock

Dr. Lal PathLabs Limited, Annual General Meeting, Jun 29, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Dr. Lal PathLabs Limited to Report Q4, 2024 Results on May 10, 2024

Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024

MD & Director recently sold ₹33m worth of stock

MD & Director recently sold ₹23m worth of stock

MD & Director recently sold ₹43m worth of stock

Upcoming dividend of ₹12.00 per share at 0.7% yield

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24

Dr. Lal PathLabs Limited to Report Q3, 2024 Results on Feb 01, 2024

Chief Executive Officer recently sold ₹7.6m worth of stock

Chief Executive Officer recently sold ₹2.6m worth of stock

Non Executive Director recently sold ₹7.8m worth of stock

Price target increased by 8.0% to ₹2,353

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2024 Results on Nov 02, 2023

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023

Dr. Lal PathLabs Limited Announces Change in Directorate

Dr. Lal PathLabs Limited Announces Change in Directorate

MD & Director recently sold ₹32m worth of stock

Upcoming dividend of ₹12.00 per share at 0.5% yield

Price target increased by 7.2% to ₹2,091

Dr. Lal PathLabs Limited, Annual General Meeting, Sep 12, 2023

Dr. Lal Pathlabs Limited Proposes Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings released: EPS: ₹9.95 (vs ₹6.97 in 1Q 2023)

MD & Director recently sold ₹41m worth of stock

MD & Director recently sold ₹43m worth of stock

Dr. Lal Pathlabs Limited Approves Appointment of Vinay Gujral as Company Secretary

Full year 2023 earnings: EPS and revenues miss analyst expectations

MD & Director recently sold ₹14m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹41m worth of stock

Rajat Kalra Resigns as Company Secretary and Compliance Officer of Dr. Lal Pathlabs Limited, Effective on or Before May 04, 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited (NSEI:LALPATHLAB) agreed to acquire additional 10% stake in Aprl Pathlabs Private Limited for INR 7.5 million.

Dr. Lal PathLabs Limited to Report Q3, 2023 Results on Feb 02, 2023

Chief Executive Officer recently sold ₹3.6m worth of stock

MD & Director recently sold ₹48m worth of stock

MD & Director recently sold ₹61m worth of stock

MD & Director recently sold ₹57m worth of stock

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited to Report Q2, 2023 Results on Nov 08, 2022

MD & Director recently sold ₹33m worth of stock

Non Executive Director recently sold ₹2.5m worth of stock

MD & Director recently sold ₹117m worth of stock

Dr. Lal Pathlabs Limited Declares an Interim Dividend for the Financial Year 2022-23, Payable on or Before August 26, 2022

First quarter 2023 earnings: EPS misses analyst expectations

Dr. Lal PathLabs Limited to Report Q1, 2023 Results on Jul 28, 2022

Dr. Lal Pathlabs Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Non-Executive Director recently sold ₹164m worth of stock

Price target decreased to ₹2,536

Upcoming dividend of ₹6.00 per share

Dr. Lal Pathlabs Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Investor sentiment improved over the past week

Chief Executive Officer recently sold ₹4.0m worth of stock

Consensus EPS estimates fall by 16%

Price target decreased to ₹2,829

Dr. Lal Pathlabs Limited Proposes Final Dividend for the Year Ended March 31, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Dr. Lal PathLabs Limited, Annual General Meeting, Jun 30, 2022

Dr. Lal PathLabs Limited to Report Q4, 2022 Results on May 17, 2022